Literature DB >> 18679122

Increased mortality of ventilated patients with endotracheal Pseudomonas aeruginosa without clinical signs of infection.

Hanjing Zhuo1, Katherine Yang, Susan V Lynch, Rachel H Dotson, David V Glidden, Gaurav Singh, W Richard Webb, Brett M Elicker, Oscar Garcia, Ronald Brown, Yoriko Sawa, Benoît Misset, Jeanine P Wiener-Kronish.   

Abstract

OBJECTIVE: To investigate the frequency and outcomes of ventilated patients with newly acquired large burdens of Pseudomonas aeruginosa and to test the hypothesis that large quantities of bacteria are associated with adverse patient outcomes.
DESIGN: A prospective, single-center, observational, cohort study.
SETTING: Medical-surgical intensive care units in a tertiary care university hospital. PATIENTS: All adult patients requiring > or = 48 hrs of mechanical ventilation and identified as having newly acquired P. aeruginosa in their lower respiratory tracts between October 2002 and April 2006.
INTERVENTIONS: None.
MEASUREMENTS AND MAIN RESULTS: Daily surveillance cultures of endotracheal aspirates were performed on patients intubated > or = 48 hrs; 69 patients with newly acquired P. aeruginosa were enrolled. Daily P. aeruginosa quantification of endotracheal aspirates was performed; clinical signs of infection were noted. Of 45 patients with high P. aeruginosa burdens (> or = 1,000,000 colony-forming units/mL in endotracheal aspirates; > or = 10,000 colony-forming units/mL in bronchoalveolar-lavage), 17 (37.8%) patients did not meet clinical criteria for ventilator-associated pneumonia and had a statistically significant higher risk of death (adjusted hazard ratio, 37.53; 95% confidence interval, 3.79-371.96; p = 0.002) when compared with the patients who had P. aeruginosa ventilator-associated pneumonia. When excluding the ten patients who had ventilator-associated pneumonia attributed to bacteria other than P. aeruginosa or attributed to multiple bacteria including P. aeruginosa, the risk of death remained statistically significant (adjusted hazard ratio, 23.98; 95% confidence interval: 2.49-230.53; p = 0.006). Furthermore, more patients with high P. aeruginosa burdens secreted the type III secretion facilitator protein, PcrV (p = 0.01).
CONCLUSIONS: A group of patients with large burdens of P. aeruginosa who did not meet clinical criteria for ventilator-associated pneumonia had an increased risk of death when compared with patients who had high P. aeruginosa burdens and met ventilator-associated pneumonia criteria. Patients with high P. aeruginosa burden seemed to possess more virulent strains.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18679122     DOI: 10.1097/CCM.0b013e318183f3f8

Source DB:  PubMed          Journal:  Crit Care Med        ISSN: 0090-3493            Impact factor:   7.598


  25 in total

1.  A Structure-Function-Inhibition Analysis of the Pseudomonas aeruginosa Type III Secretion Needle Protein PscF.

Authors:  Donald T Moir; Nicholas O Bowlin; Bryan J Berube; Jaden Yabut; Debra M Mills; Giang T Nguyen; Zachary D Aron; John D Williams; Joan Mecsas; Alan R Hauser; Terry L Bowlin
Journal:  J Bacteriol       Date:  2020-08-25       Impact factor: 3.490

2.  A persistent and diverse airway microbiota present during chronic obstructive pulmonary disease exacerbations.

Authors:  Yvonne J Huang; Eugenia Kim; Michael J Cox; Eoin L Brodie; Ron Brown; Jeanine P Wiener-Kronish; Susan V Lynch
Journal:  OMICS       Date:  2010-02

Review 3.  Value of lower respiratory tract surveillance cultures to predict bacterial pathogens in ventilator-associated pneumonia: systematic review and diagnostic test accuracy meta-analysis.

Authors:  Nele Brusselaers; Sonia Labeau; Dirk Vogelaers; Stijn Blot
Journal:  Intensive Care Med       Date:  2012-11-28       Impact factor: 17.440

4.  Rapid automated microscopy for microbiological surveillance of ventilator-associated pneumonia.

Authors:  Ivor S Douglas; Connie S Price; Katherine H Overdier; Robert F Wolken; Steven W Metzger; Kenneth R Hance; David C Howson
Journal:  Am J Respir Crit Care Med       Date:  2015-03-01       Impact factor: 21.405

5.  Enzymatic quorum quenching increases antibiotic susceptibility of multidrug resistant Pseudomonas aeruginosa.

Authors:  S Kiran; P Sharma; K Harjai; N Capalash
Journal:  Iran J Microbiol       Date:  2011-03

6.  PAI-1 is an essential component of the pulmonary host response during Pseudomonas aeruginosa pneumonia in mice.

Authors:  Arnaud Goolaerts; Mathieu Lafargue; Yuanlin Song; Byron Miyazawa; Mehrdad Arjomandi; Michel Carlès; Jérémie Roux; Marybeth Howard; Dale A Parks; Karen E Iles; Jean-François Pittet
Journal:  Thorax       Date:  2011-07-18       Impact factor: 9.139

7.  Clinical outcomes of type III Pseudomonas aeruginosa bacteremia.

Authors:  Ali A El-Solh; Angela Hattemer; Alan R Hauser; Ahmad Alhajhusain; Hardik Vora
Journal:  Crit Care Med       Date:  2012-04       Impact factor: 7.598

8.  Streptococcus pneumoniae and Pseudomonas aeruginosa pneumonia induce distinct host responses.

Authors:  Kevin W McConnell; Jonathan E McDunn; Andrew T Clark; W Michael Dunne; David J Dixon; Isaiah R Turnbull; Peter J Dipasco; William F Osberghaus; Benjamin Sherman; James R Martin; Michael J Walter; J Perren Cobb; Timothy G Buchman; Richard S Hotchkiss; Craig M Coopersmith
Journal:  Crit Care Med       Date:  2010-01       Impact factor: 7.598

9.  Mutations in the Pseudomonas aeruginosa needle protein gene pscF confer resistance to phenoxyacetamide inhibitors of the type III secretion system.

Authors:  Nicholas O Bowlin; John D Williams; Claire A Knoten; Matthew C Torhan; Tommy F Tashjian; Bing Li; Daniel Aiello; Joan Mecsas; Alan R Hauser; Norton P Peet; Terry L Bowlin; Donald T Moir
Journal:  Antimicrob Agents Chemother       Date:  2014-01-27       Impact factor: 5.191

10.  Activation of inflammasome signaling mediates pathology of acute P. aeruginosa pneumonia.

Authors:  Taylor S Cohen; Alice S Prince
Journal:  J Clin Invest       Date:  2013-03-08       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.